Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile
- 15 June 2007
- journal article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 853 (1-2), 88-96
- https://doi.org/10.1016/j.jchromb.2007.02.053
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With SitosterolemiaCirculation, 2004
- IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)Drug Metabolism and Disposition, 2004
- Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemiaEuropean Heart Journal, 2003
- The Yin and Yang of cholesteryl ester transfer protein and atherosclerosisClinical Science, 2002
- Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemiaThe American Journal of Cardiology, 2002
- Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.Drug Metabolism and Disposition, 2002
- Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic functionBritish Journal of Pharmacology, 2001
- Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studiesClinical Therapeutics, 2001
- A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibeClinical Therapeutics, 2001
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000